Literature DB >> 32380271

Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression.

Yena Lee1, Rodrigo B Mansur2, Elisa Brietzke3, Nicole E Carmona4, Mehala Subramaniapillai5, Zihang Pan6, Margarita Shekotikhina6, Joshua D Rosenblat2, Trisha Suppes7, Victoria E Cosgrove8, Nicole E Kramer8, Roger S McIntyre9.   

Abstract

We investigated the efficacy of tumour necrosis factor (TNF)-α antagonist infliximab on a measure of anhedonia amongst individuals with bipolar I/II depression (ClinicalTrials.gov identifier NCT02363738). Adults (ages 18-65) with bipolar I/II disorder currently experiencing a major depressive episode with a higher probability of inflammatory activity (i.e., meeting one or more of the following inflammatory/metabolic criteria: obesity and dyslipidemia/hypertension, daily cigarette smoking, diabetes mellitus, migraine, inflammatory bowel disease, and/or C-reactive protein level of ⩾5 mg/L) were enrolled in a double-blind, 12-week clinical trial of adjunctive infliximab (5 mg/kg) and saline control, which were administered at weeks 0, 2, and 6. The primary outcome measure for the present secondary analysis was change in the Snaith-Hamilton Pleasure Scale (SHAPS) total score between placebo- and infliximab-treated subjects from baseline to weeks 6 and 12. Plasma concentrations of TNF-α and soluble TNF receptors (sTNFR) 1 and 2 were assessed at weeks 0, 2, 6, and 12. Sixty eligible adults received treatment with infliximab (n=29) or placebo (n=31); 47 subjects completed the study (infliximab: n=21, placebo: n=26). Overall, infliximab-randomized subjects exhibited significantly larger increases in SHAPS total score, denoting greater reductions in anhedonic symptoms, when compared to placebo-randomized subjects (treatment × time interaction effect: χ2=7.15,df=2,p=0.03). Anti-anhedonic efficacy was moderated by baseline plasma levels of TNF-α and sTNFR1, but not by changes in TNF-α or sTNFR1 concentrations. Baseline and changes in sTNFR2 concentrations did not moderate anti-anhedonic efficacy. Infliximab significantly improved a measure of anhedonia relative to placebo in adults with bipolar I/II depression at week 6; intervention efficacy was not sustained 6 weeks after the final infusion.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anhedonia; Bipolar disorder; Depression; Mood disorders; Treatment efficacy

Mesh:

Substances:

Year:  2020        PMID: 32380271     DOI: 10.1016/j.bbi.2020.04.063

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  11 in total

1.  Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study.

Authors:  Mandakh Bekhbat; Zhihao Li; Namrataa D Mehta; Michael T Treadway; Michael J Lucido; Bobbi J Woolwine; Ebrahim Haroon; Andrew H Miller; Jennifer C Felger
Journal:  Mol Psychiatry       Date:  2022-08-04       Impact factor: 13.437

Review 2.  Inflammation as a Pathophysiologic Pathway to Anhedonia: Mechanisms and Therapeutic Implications.

Authors:  Mandakh Bekhbat; Michael T Treadway; Jennifer C Felger
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 3.  Anhedonia and Suicide.

Authors:  Randy P Auerbach; David Pagliaccio; Jaclyn S Kirshenbaum
Journal:  Curr Top Behav Neurosci       Date:  2022

4.  Linking childhood trauma and cytokine levels in depressed adolescents.

Authors:  Manivel Rengasamy; Anna Marsland; Lora McClain; Tessa Kovats; Thomas Walko; Lisa Pan; Rebecca B Price
Journal:  Psychoneuroendocrinology       Date:  2021-08-27       Impact factor: 4.905

5.  Sex differences in circulating inflammatory mediators as a function of substance use disorder.

Authors:  April C May; Kaiping Burrows; Leandra K Figueroa-Hall; Namik Kirlic; Evan J White; Ryan Smith; Hamed Ekhtiari; Martin P Paulus; Jonathan Savitz; Jennifer L Stewart
Journal:  Drug Alcohol Depend       Date:  2021-02-15       Impact factor: 4.852

Review 6.  Anti-TNF-α Compounds as a Treatment for Depression.

Authors:  Sarit Uzzan; Abed N Azab
Journal:  Molecules       Date:  2021-04-19       Impact factor: 4.411

7.  Anhedonia difference between major depressive disorder and bipolar disorder II.

Authors:  Xinyu Fang; Dandan Wang; Wei Tang; Hongyang Liu; Xiangrong Zhang; Chen Zhang
Journal:  BMC Psychiatry       Date:  2021-10-27       Impact factor: 3.630

Review 8.  Influences of dopaminergic system dysfunction on late-life depression.

Authors:  Warren D Taylor; David H Zald; Jennifer C Felger; Seth Christman; Daniel O Claassen; Guillermo Horga; Jeffrey M Miller; Katherine Gifford; Baxter Rogers; Sarah M Szymkowicz; Bret R Rutherford
Journal:  Mol Psychiatry       Date:  2021-08-17       Impact factor: 15.992

9.  Transdiagnostic inflammatory subgroups among psychiatric disorders and their relevance to role functioning: a nested case-control study of the ALSPAC cohort.

Authors:  Jonah F Byrne; Colm Healy; David Mongan; Subash Raj Susai; Stan Zammit; Melanie Fӧcking; Mary Cannon; David R Cotter
Journal:  Transl Psychiatry       Date:  2022-09-09       Impact factor: 7.989

10.  Longitudinal relationships of cytokines, depression and anhedonia in depressed adolescents.

Authors:  Manivel Rengasamy; Anna Marsland; Lora McClain; Tessa Kovats; Thomas Walko; Lisa Pan; Rebecca B Price
Journal:  Brain Behav Immun       Date:  2020-09-10       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.